Oral Answers to Questions

Debate between Mary Glindon and George Freeman

Tuesday 7th June 2022 Commons Chamber

[The Parliamentary Under-Secretary of State for Business, Energy and Industrial Strategy (George Freeman)]

Milton Keynes has been slowly becoming a globally recognised innovation hub on the Oxford-Cambridge arc, particularly on autonomous vehicles and with the connected places catapult. May I take this opportunity to congratulate my hon. Friend and Milton Keynes on achieving city status as part of the jubilee celebrations? I assure him that our funding allocation mechanism is designed to support emerging clusters such as Milton Keynes.

[Mary Glindon (North Tyneside) (Lab)]

T4. What is the Department doing, working with the Department of Health and Social Care, to improve the recovery of cancer trials and clinical research more broadly? Will the Minister meet me and Cancer Research UK to discuss how the rate of recovery can catch up with comparable countries post pandemic?

[George Freeman]

I would be delighted to meet the hon. Lady. We have allocated £8 billion over the next three years for life science and medical research across the Medical Research Council, the National Institute for Health and Care Research, and all relevant agencies. We will launch a cancer mission shortly and I would be delighted to talk to her about it.

Oral Answers to Questions

Debate between Mary Glindon and George Freeman

Thursday 24th October 2019 Commons Chamber

[The Minister of State, Department for Transport (George Freeman)]

I am delighted to say that the noble Baroness Vere who deals with these issues and I met yesterday, and we both commend my hon. Friend for her leadership on this issue. This has been a very serious emergency situation, causing huge congestion in her part of the world, and we are determined to ensure that we get the solution right. That means not necessarily rebuilding what was there before, but getting a proper state-of-the-art solution.

[Mary Glindon (North Tyneside) (Lab)]

T7. At Highways England, a Government-owned company of which the Secretary of State is the sole shareholder, over 60 executives—mostly men—now enjoy six-figure salaries, while the vast majority of staff have been told to expect their pay increases to remain capped at 1% until 2025. When will the new shareholder be challenging company directors to address these pay disparities?

Oral Answers to Questions

Debate between Mary Glindon and George Freeman

Tuesday 22nd March 2016 Commons Chamber

[George Freeman]

We are engaged in active discussions with the various parties, including charities such as Cancer Research UK, and we have received some interesting submissions from some of the research institutes. Over the coming weeks, we will consider how best to put that £5 million from the Government to work in order to maximise inward investment and build UK leadership in this important centre.

[Mary Glindon (North Tyneside) (Lab)]

14. What steps he is taking to ensure that people with muscle-wasting conditions who require a cough assist machine have access to such a machine, commissioned in the community by their clinical commissioning group.

Adult Stem Cells and Life Sciences

Debate between Mary Glindon and George Freeman

Tuesday 15th September 2015 Commons Chamber

[George Freeman]

My hon. Friend makes a good point. As in some other sectors, such as malaria, where the commercial models are not as well developed or as clear, there is a role for the Government, which is why we have set up the strategy and the partnerships. By de-risking and supporting the deep science in the early stages and bringing forward these partnerships of support, we hope to make it a sector in which more and more companies are beginning to see a return, and then they will start to invest their own money. All the indications are that that is beginning to happen here in the UK.

[Mary Glindon]

Will the Minister therefore ensure that the Government will continue to support the science budget in the years ahead?

[George Freeman]

Much as I would like to, I cannot take on the role of my right hon. Friend the Chancellor and announce the results of the autumn statement. I hope that the hon. Lady will see that our commitment to, and support for, the sector is clear. I am confident that we will see a continuation of that support for science in the autumn statement. We all know that funding is tight. The key is to demonstrate clinical impact and partnerships of support with companies.

I think that this is a great success story. I pay tribute once again to the Anthony Nolan trust, whose partnership with the NHS is genuinely changing outcomes for patients.

Question put and agreed to.